Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe
Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe
复制标题
DOI：
10.3390/cancers12071841
复制
发表时间：
2020-07-01
期刊：
影响因子：
5.2
通讯作者：
Gennari, Alessandra
中科院分区：
文献类型：
--
作者：
Pinato, David J.;Lee, Alvin J. X.;Gennari, Alessandra
我们描述了回顾性、多中心观察性OnCovid研究中欧洲COVID-19最初爆发期间癌症患者的结局。我们从英国、意大利和西班牙的8个中心确定了204名年龄>18岁（平均= 69岁）的癌症患者，他们在2020年2月26日至4月1日期间被诊断为COVID-19。共127例（62%）为男性，184例（91%）诊断为实体恶性肿瘤，103例（51%）为非转移性疾病。共161例（79%）合并症>1例。共有141名（69%）患者发生了>1起COVID-19并发症。共有36人（19%）被升级为高度依赖或重症监护。共有59人（29%）死亡，53人（26%）出院，92人（45%）住院幸存。年龄>65岁（36% vs. 16%）、合并症>2种（40% vs. 18%）和COVID-19并发症>1种（38% vs. 4%，p = 0.004）的患者死亡率较高。多变量分析证实，年龄> 65岁和>2种合并症可预测患者死亡率，与肿瘤分期、活动性恶性肿瘤或抗癌治疗无关。在欧洲SARS-CoV-2感染的早期爆发期间，共病负担和年龄增长预测了癌症患者的不良疾病病程。正在进行的OnCovid研究将使我们能够比较COVID-19大流行初期和后期癌症患者的风险和结局。
We describe the outcomes in cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. We identified 204 cancer patients from eight centers in the United Kingdom, Italy, and Spain aged >18 (mean = 69) and diagnosed with COVID-19 between 26 February and 1 April 2020. A total of 127 (62%) were male, 184 (91%) had a diagnosis of solid malignancy, and 103 (51%) had non-metastatic disease. A total of 161 (79%) had >1 co-morbidity. A total of 141 (69%) patients had >1 COVID-19 complication. A total of 36 (19%) were escalated to high-dependency or intensive care. A total of 59 (29%) died, 53 (26%) were discharged, and 92 (45%) were in-hospital survivors. Mortality was higher in patients aged >65 (36% vs. 16%), in those with >2 co-morbidities (40% vs. 18%) and developing >1 complication from COVID-19 (38% vs. 4%,p= 0.004). Multi-variable analyses confirmed age > 65 and >2 co-morbidities to predict for patient mortality independent of tumor stage, active malignancy, or anticancer therapy. During the early outbreak of SARS-CoV-2 infection in Europe co-morbid burden and advancing age predicted for adverse disease course in cancer patients. The ongoing OnCovid study will allow us to compare risks and outcomes in cancer patients between the initial and later stages of the COVID-19 pandemic.